We are delighted to announce our friends and long-time supporters of the charity, Trevor and Lucy, are our new Action Duchenne Ambassadors! Lucy …
Trevor and Lucy become Ambassadors for Action DuchenneRead More

19 March 2019 by abzali123
We are delighted to announce our friends and long-time supporters of the charity, Trevor and Lucy, are our new Action Duchenne Ambassadors! Lucy …
Trevor and Lucy become Ambassadors for Action DuchenneRead More

26 February 2019 by abzali123
Raxone (also known as Idebenone) is a drug produced by Santhera Pharmaceuticals, which treats several conditions and has the potential to treat …

26 February 2019 by abzali123
In a press release, Santhera Pharmaceuticals has announced results from the SYROS study, where long-term treatment with idebenone (also known as …

15 February 2019 by abzali123
This weekend our Director of Research, Neil Bennett, and our CEO, Shelley Simmonds, are in Rome attending the Duchenne Parent Project International …

14 February 2019 by abzali123
Last weekend, our wonderful supporters Stoke By Nayland Golf Club held their much anticipated raffle draw. The prize was a week in a luxury villa …

12 February 2019 by abzali123
Solid Biosciences have announced preliminary data from their phase 1/2 IGNITE-DMD clinical trial that is testing the safety and effectiveness of …
Solid Biosciences announce preliminary trial resultsRead More

6 February 2019 by abzali123
PTC Therapeutics had their annual kick-off meeting in Cascais, outside of Lisbon from 28th January to the 1st of February. Cormac Fegan, age 8, and …

30 January 2019 by abzali123
An update from our Scottish Advocacy Officer, John Miller: "At a Disability Cross Party meeting on the 27th November 2018, the Secretary of …

23 January 2019 by abzali123
Following meetings with the FDA (the medicines regulator in the US), Capricor Therapeutics yesterday issued an update yesterday on it’s HOPE-2 …

22 January 2019 by abzali123
If you're supporting one of our many Duchenne research projects, here's an idea of where your money goes, and how every penny …

24 December 2018 by abzali123
Catabasis has announced that the phase 3 trial of edasalonexent is now recruiting at 9 centres across the USA and that regulatory approval for the …

20 December 2018 by abzali123
Sarepta therapeutics has today announced that they have completed the submission of a USA application for accelerated approval of golodirsen …
Sarepta completes accelerated approval application for golodirsenRead More
Action Duchenne
5th Floor, Mariner House
62 Prince Street
Bristol
BS1 4QD
07535 498 506
info@actionduchenne.org
